Dr. Minar is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3333 Burnet Ave
# 2010
Cincinnati, OH 45229Phone+1 513-636-4415Fax+1 513-636-7805
Summary
- Dr. Phillip Minar, MD, is a pediatric gastroenterologist based in Cincinnati, OH. He had his education at the Medical College of Wisconsin for both his medical degree and his residency in pediatrics. Dr. Minar then completed a fellowship in pediatric gastroenterology at Cincinnati Children's Hospital Medical Center, where he also currently serves as an Associate Professor of Pediatrics. He concentrates his practice on pediatric inflammatory bowel disease. He has numerous publications to his name in reputable journals, focused on topics such as the impact of inflammatory biomarkers on anti-TNF therapy in pediatric Crohn's disease, and the role of therapeutic drug monitoring in children. Dr. Minar is leading a multicenter clinical trial entitled "Precise Infliximab Exposure and Pharmacodynamic Control to Achieve Deep Remission in Pediatric Crohn's Disease (REMODEL-CD)."
Education & Training
Cincinnati Children's Hospital Medical CenterFellowship, Pediatric Gastroenterology, 2010 - 2013
Medical College of Wisconsin Affiliated HospitalsResidency, Pediatrics, 2007 - 2010- Medical College of WisconsinClass of 2007
Certifications & Licensure
KY State Medical License 2020 - 2026
OH State Medical License 2010 - 2026
IN State Medical License 2020 - 2025
WI State Medical License 2009 - 2013
American Board of Pediatrics Pediatrics- American Board of Pediatrics Pediatric Gastroenterology
Clinical Trials
- Precision Crohn's Disease Management Utilizing Predictive Protein Panels (ENvISION) Start of enrollment: 2019 Oct 16
- Precise Infliximab Exposure and Pharmacodynamic Control Start of enrollment: 2023 Jul 01
Publications & Presentations
PubMed
- Editorial: Baseline Drug Clearance Predicts Outcomes in Children With Inflammatory Bowel Disease Treated With Vedolizumab.Courtney Bartel, Phillip Minar
Alimentary Pharmacology & Therapeutics. 2025-01-31 - Circulating and Magnetic Resonance Imaging Biomarkers of Intestinal Fibrosis in Small Bowel Crohn's Disease.Jonathan R Dillman, Jean A Tkach, Joel G Fletcher, David H Bruining, Aiming Lu
Inflammatory Bowel Diseases. 2025-01-24 - HLA DQA1*05 and risk of anti-TNF treatment failure and anti-drug antibody development in children with Crohn's Disease: HLA DQA1*05 and Pediatric Crohn's Disease.Jeremy Adler, Joseph A Galanko, Rana Ammoury, Keith J Benkov, Athos Bousvaros
The American Journal of Gastroenterology. 2024-10-18
Grant Support
- Precise Infliximab Exposure and Pharmacodynamic Control to Achieve Deep Remission in Pediatric Crohn's DiseaseNIDDKPresent
- K23- Therapeutic Monitoring and Targeting of Neutrophil Activation in Pediatric IBDNIH NIDDKPresent
- Redefining Deep Remission in Pediatric Crohn's DiseaseNASPGHAN Foundation/CCFAPresent
Professional Memberships
- NASPGHANMember
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
